| abstract |
A compound of formula (1), wherein A represents (II), (III), (IV) or (V), D represents oxygen or sulfur; E represents a single bond, oxygen, sulfur, or NR10; R represents hydrogen or methyl; Ar1 represents a 5- or 6-membered aromatic or heteroaromatic ring containing zero to three nitrogen atoms, zero or one oxygen atom, and zero or one sulfur atom; Ar2 represents a 5- or 6-membered aromatic or beteroaromatic ring containing zero to three nitrogen atoms, zero or one oxygen atom, and zero or one sulfur atom or, an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system containing zero to three nitrogen atoms, zero to one oxygen atom, and zero to one sulfur atom; the aromatic rings Ar1 and Ar2 are optionally substituted with one or three substituents selected from: halogen, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, CN, NO2, NR1R2, CH2NR1R2, OR3, CH2OR3, CO2R4, CF3; R1, R2 and R3 are independently C1-4alkyl, aryl. heteroaryl, C(O)R5, C(O)NHR6, C(O)R7, SO2R8 or R1 and R2 may together be (CH2)jG(CH2)k where G is oxygen, sulfur, NR9, or a bond; j is 2 to 4; k is 0 to 2; R4, R5, R6, R7, R8, R9, and R10 are independently C1-4alkyl. aryl, or heteroaryl; or an enantiomer thereof and pharmaceutically acceptable salts thereof; with the provisos that: (1) if D represents oxygen, E represents a single bond, and A represents (II) and either Ar1 or Ar2 represents a pyrazole ring, then all optional substituents on the pyrazole ring shall be hydrogen; and (2) if Ar1 represents a pyridine ring, Ar2 represents an aryl ring, and A represents (II), then all optional substituents on the pyridine ring shall be hydrogen; and (3) formula (I) does not represent (a); processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders. (I) |